The rising interest in potent weight management has spurred considerable investigation into groundbreaking treatments. Currently, Retatrutide, a twin-action GIP and glucagon-like peptide-1 (GLP-1) receptor activator , has exhibited promising results in medical trials, implying potential for substantial weight loss . Therefore, several individuals a